EUVIMEDEUVIMED entdecken
Open Access

Prognostic Impact of CYP2C19 Genotypes on Long‐Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention

Ju Hyeon Kim iD, Seung-Jun Lee iD, Jung-Joon Cha iD, Jae Hyoung Park iD, Soon Jun Hong iD, Tae Hoon Ahn iD, Byeong-Keuk Kim iD, Kiyuk Chang iD, Yongwhi Park iD, Young Bin Song iD, Sung Gyun Ahn iD, Jung-Won Suh iD und 9 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.032248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Ju Hyeon Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul South Korea. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Clopidogrel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carriers of CYP2C19 loss‐of‐function alleles have increased adverse events after percutaneous coronary intervention, but limited data are available for older patients. We aimed to evaluate the prognostic impact of CYP2C19 genotypes on clinical outcomes in older patients after percutaneous coronary intervention. Methods and Results The study included 1201 older patients (aged ≥75 years) who underwent percutaneous coronary intervention and received clopidogrel‐based dual antiplatelet therapy in South Korea. Patients were grouped on the basis of CYP2C19 genotypes. The primary outcome was 3‐year major adverse cardiac events, defined as a composite of cardiac death, myocardial infarction, and stent thrombosis. Older patients were grouped into 3 groups: normal metabolizer (36.6%), intermediate metabolizer (48.1%), and poor metabolizer (15.2%). The occurrence of the primary outcome was significantly different among the groups (3.1, 7.0, and 6.2% in the normal metabolizer, intermediate metabolizer, and poor metabolizer groups, respectively; P =0.02). The incidence rate of all‐cause death at 3 years was greater in the intermediate metabolizer and poor metabolizer groups (8.1% and 9.2%, respectively) compared with that in the normal metabolizer group (3.5%, P =0.03) without significant differences in major bleeding. In the multivariable analysis, the intermediate metabolizer and poor metabolizer groups were independent predictors of 3‐year clinical outcomes.

Conclusions

In older patients, the presence of any CYP2C19 loss‐of‐function allele was found to be predictive of a higher incidence of major adverse cardiac events within 3 years following percutaneous coronary intervention. This finding suggests a need for further investigation into an optimal antiplatelet strategy for older patients. Registration URL: https://clinicaltrials.gov . Identifier: NCT04734028.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Percutaneous Coronary InterventionPlatelet Aggregation InhibitorsClopidogrelGenotypeHumansMaleFemaleAgedRepublic of KoreaAged, 80 and overPrognosisTreatment OutcomeTime FactorsCoronary Artery DiseaseRisk FactorsDual Anti-Platelet TherapyRisk AssessmentAge FactorsMyocardial InfarctionPharmacogenomic Variants

Stichwörter der Autor:innen

agedcytochrome P‐450 2C19geneticsgenotypepercutaneous coronary interventionpolymorphism

Substanzen

Cytochrome P-450 CYP2C19Platelet Aggregation InhibitorsClopidogrelCYP2C19 protein, human

Autor:innen und Institutionen

  • Department of Cardiology, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul South Korea.
  • Severance Cardiovascular Hospital Seoul South Korea.
  • Department of Cardiology Heart and Brain Institute, Chung-Ang University Gwang-Myeong Hospital, Chung-Ang University College of Medicine Gwangmyeong-si South Korea.
  • Division of Cardiology, Department of Internal Medicine College of Medicine, Catholic University of Korea Seoul South Korea.
  • Department of Internal Medicine Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital Changwon South Korea.
  • Division of Cardiology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea.

ORCID-Profile: Ju Hyeon Kim, Seung-Jun Lee, Jung-Joon Cha, Jae Hyoung Park, Soon Jun Hong, Tae Hoon Ahn, Byeong-Keuk Kim, Kiyuk Chang, Yongwhi Park, Young Bin Song, Sung Gyun Ahn, Jung-Won Suh, Sang Yeub Lee, Jung Rae Cho, Ae-Young Her, Young-Hoon Jeong, Hyo-Soo Kim, Moo Hyun Kim, Eun-Seok Shin, Do-Sun Lim

Zitieren

APA

Kim, J. H., Lee, S. J., Cha, J. J., Park, J. H., Hong, S. J., Ahn, T. H., Kim, B. K., Chang, K., Park, Y., Song, Y. B., Ahn, S. G., Suh, J. W., Lee, S. Y., Cho, J. R., Her, A. Y., Jeong, Y. H., Kim, H. S., Kim, M. H., Shin, E. S., …, & PTRG‐DES Consortium Investigators (2024). Prognostic Impact of CYP2C19 Genotypes on Long‐Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.032248

Vancouver

Kim JH, Lee SJ, Cha JJ, Park JH, Hong SJ, Ahn TH, et al. Prognostic Impact of CYP2C19 Genotypes on Long‐Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.032248

BibTeX
@article{Kim2024,
  author = {Kim, Ju Hyeon and Lee, Seung-Jun and Cha, Jung-Joon and Park, Jae Hyoung and Hong, Soon Jun and Ahn, Tae Hoon and Kim, Byeong-Keuk and Chang, Kiyuk and Park, Yongwhi and Song, Young Bin and Ahn, Sung Gyun and Suh, Jung-Won and Lee, Sang Yeub and Cho, Jung Rae and Her, Ae-Young and Jeong, Young-Hoon and Kim, Hyo-Soo and Kim, Moo Hyun and Shin, Eun-Seok and Lim, Do-Sun and PTRG‐DES Consortium Investigators, PTRG‐DES Consortium Investigators},
  title = {Prognostic Impact of CYP2C19 Genotypes on Long‐Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.032248}
}
Kostenlos starten →